Depakine (DrugBank: -)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 102 | ルビンシュタイン・テイビ症候群 | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2011-003784-30-FR (EUCTR) | 13/12/2011 | Rubinstein-Taybi syndrome: approach to functional imaging and therapeutic trial | Rubinstein-Taybi syndrome: approach to functional imaging and therapeutic trial - RUBIVAL | Rubinstein-Taybi Syndrome MedDRA version: 14.1;Level: PT;Classification code 10039281;Term: Rubinstein-Taybi syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: Depakine | CHU de bordeaux | NULL | NA | Female: yes Male: yes | Phase 2 | France |